Cancers, Volume 16, Issue 6
2024 March-2 - 165 articles
Cover Story: The BCL2 inhibitor venetoclax combined with the hypomethylating agent azacitidine is the new therapeutic standard for elderly or unfit acute myeloid leukemia patients. Despite a 65% composite response rate, overall survival is about 14 months, underlying the need for new therapeutics with improved efficacy and low toxicity. Gene mutations associated with resistance or relapse are TP53, signaling mutations, and the newly described BAX mutations. Venetoclax-based triplet therapies, including IDH and FLT3 inhibitors or menin inhibitors, are under investigation to improve patient outcomes. A better comprehension of genomic and non-genomic evolution upon treatment and the interplay between genomic alterations and apoptosis will allow us to tackle resistance mechanisms in the future. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.